Biosynthetic Technologies Inks Patent License Agreement with Cayman Chemical for the Global Pharmaceutical and R&D Markets
Indianapolis, IN, September 05, 2019 --(PR.com)-- Biosynthetic Technologies (BT) today announced it has signed on with Cayman Chemical for the production and distribution of novel Estolide compounds for pharmaceutical testing applications. BT is excited to partner with Cayman Chemical to provide discovery and pre-clinical development services to the global pharmaceutical, biotechnology, and academic research markets using Estolide products (also known as fatty acid hydroxy fatty acids or FAHFAs) for research purposes.
“We are thrilled to be partnering with the team at Cayman Chemical. In the last few years, there have been some exciting developments involving optically active FAHFAs in pharma and, in particular, therapeutics directed to diabetes and inflammatory diseases. We are happy to have found a strong partner with Cayman Chemical, which not only has a reputation for quality, but has a long history of manufacturing and distributing novel compounds for pharmaceutical research. We have no doubt that this partnership with Cayman Chemical will help to demonstrate that Estolides are truly amazing compounds with far-reaching applications on a global scale,” says Jeremy Forest, co-inventor and EVP of Strategy at Biosynthetic Technologies.
“We are delighted to offer the innovative products developed by Biosynthetic Technologies to our partners and customers in the life science research community. BT is well known as a leader in the development and manufacture of novel, environmentally responsible, and sustainable high-performance biobased synthetic materials. BT’s commitment to excellence was solidified with the recent additions to its R&D team. We are excited to partner with this team of visionaries as they broaden the scope of their synthetic product lines to the life sciences,” says Stephen Barrett, Vice President of Research, Development, and Production at Cayman Chemical. “Cayman’s notable history in the lipid areas and life science research tools and services coupled with BT’s hunt for novel therapies for the treatment of chronic diseases creates a winning combination and works toward fulfilling Cayman’s mission to help make research possible.”
The terms of the license agreement provide Cayman Chemical with global rights to make and sell FAHFA products for R&D purposes in the development of pharmaceutical products. The financial terms of the license agreement were not disclosed.
About Biosynthetic Technologies:
Biosynthetic Technologies manufactures a revolutionary new class of biobased synthetic compounds called Estolides that are made from organic fatty acids found in various bio-derived oils. These highly functional biosynthetic oils have numerous uses in lubricant, automotive, marine, pharma, and personal care applications and can be used as the primary base oil of a formulation, a component of a base oil co-blend, or even as an additive. In addition to their high-performance properties, these renewable oils are biodegradable and nontoxic. Biosynthetic Technologies strives to make their mark on the world by delivering innovations for a sustainable future. Biosynthetic Technologies recently secured Series A financing led by HG Ventures, a division of The Heritage Group, based in Indianapolis, IN.
About Cayman Chemical:
Cayman Chemical Company helps make research possible by supplying scientists worldwide with biochemical tools used to understand cancer, neurochemistry, oxidative injury, endocrinology, atherosclerosis, and other human health challenges. Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others for use as research reagents and qualified standards. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination. In addition, we offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques. Cayman performs generic drug development and production in both Ann Arbor, Michigan and Neratovice, Czech Republic.
“We are thrilled to be partnering with the team at Cayman Chemical. In the last few years, there have been some exciting developments involving optically active FAHFAs in pharma and, in particular, therapeutics directed to diabetes and inflammatory diseases. We are happy to have found a strong partner with Cayman Chemical, which not only has a reputation for quality, but has a long history of manufacturing and distributing novel compounds for pharmaceutical research. We have no doubt that this partnership with Cayman Chemical will help to demonstrate that Estolides are truly amazing compounds with far-reaching applications on a global scale,” says Jeremy Forest, co-inventor and EVP of Strategy at Biosynthetic Technologies.
“We are delighted to offer the innovative products developed by Biosynthetic Technologies to our partners and customers in the life science research community. BT is well known as a leader in the development and manufacture of novel, environmentally responsible, and sustainable high-performance biobased synthetic materials. BT’s commitment to excellence was solidified with the recent additions to its R&D team. We are excited to partner with this team of visionaries as they broaden the scope of their synthetic product lines to the life sciences,” says Stephen Barrett, Vice President of Research, Development, and Production at Cayman Chemical. “Cayman’s notable history in the lipid areas and life science research tools and services coupled with BT’s hunt for novel therapies for the treatment of chronic diseases creates a winning combination and works toward fulfilling Cayman’s mission to help make research possible.”
The terms of the license agreement provide Cayman Chemical with global rights to make and sell FAHFA products for R&D purposes in the development of pharmaceutical products. The financial terms of the license agreement were not disclosed.
About Biosynthetic Technologies:
Biosynthetic Technologies manufactures a revolutionary new class of biobased synthetic compounds called Estolides that are made from organic fatty acids found in various bio-derived oils. These highly functional biosynthetic oils have numerous uses in lubricant, automotive, marine, pharma, and personal care applications and can be used as the primary base oil of a formulation, a component of a base oil co-blend, or even as an additive. In addition to their high-performance properties, these renewable oils are biodegradable and nontoxic. Biosynthetic Technologies strives to make their mark on the world by delivering innovations for a sustainable future. Biosynthetic Technologies recently secured Series A financing led by HG Ventures, a division of The Heritage Group, based in Indianapolis, IN.
About Cayman Chemical:
Cayman Chemical Company helps make research possible by supplying scientists worldwide with biochemical tools used to understand cancer, neurochemistry, oxidative injury, endocrinology, atherosclerosis, and other human health challenges. Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others for use as research reagents and qualified standards. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination. In addition, we offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques. Cayman performs generic drug development and production in both Ann Arbor, Michigan and Neratovice, Czech Republic.
Contact
Cayman Chemical Company
Jason Truskowski
(734) 975-3897
www.caymanchem.com
Jason Truskowski
(734) 975-3897
www.caymanchem.com
Contact
Categories